- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01399983
Standardization of 6 Minute Walk Test
Assessment of Exercise Capacity and Standardization of Six Minute Walk Test in Patients With Pulmonary Hypertension
The 6 minute walk (6MW) gives information about the exercise capacity and it is an important tool for clinical decisions and for the prognostic evaluation of PH patients. The test is technically simple to perform, inexpensive and reproducible. During the 6MW O2 saturation, heart rate, walking distance (in this study after every minute) and the level of dyspnea (BORG-dyspnea scale) may be recorded; however, at present, mainly the walking distance is evaluated. The test is sometimes criticized, because of the dependence on the patient's motivation.
The purpose of the present study is to standardize the test by the incorporation of objective factors. The investigators are correlating the change of heart rate and dyspnea (BORG scale) with the achieved walking distance during subsequent examinations performed with different effort.
Study Overview
Status
Conditions
Detailed Description
On two different days the patients have to absolve four 6MW on different levels of effort - on both days a traditional test will be performed and additionally a test with more effort or with less effort. The order of the tests will be randomized. These two days of the examinations should be within a maximum of three months, provided that there is no sign of relevant clinical changes. After every minute the walking distance is determined. Heart rate and the O2 saturation are measured by pulsoxymetry during the whole test. Every two minutes the patients are asked about their dyspnea (Borg scale).
The purpose of the present study is to standardize the test by the incorporation of objective factors and to detect the correlation between the walking distance and the level of effort during exercise. The investigators expect that the reliability and objectivity of 6MW may increase by the standardization.
The additionally performed cardiopulmonary exercise testing helps to evaluate and stratify patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8036
- Medical University of Graz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diagnosis of pulmonary hypertension or exercise-induced pulmonary hypertension by right heart catheterisation
- informed consent
Exclusion Criteria:
- Myocardiac Infarct within the last 12 months
- Uncontrolled ventricular arrhythmia
- Uncontrolled bradycardic or tachycardic supraventricular arrhythmia
- relevant operations within the last 12 weeks
- change of the hemodynamic therapy within the last 6 weeks
- joint diseases or diseases of peripheral vessels and nerves which may make the results of the six minute walk test unreliable
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
pulmonary hypertension
patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change of six minute walk distance between baseline measurement and measurement with more effort or less effort
Time Frame: the six minute walk test with a different effort is performed 1 hour after the baseline test. The second baseline test and the missing test with a different effort takes place within three months.
|
distance at six minute walk performed by different efforts
|
the six minute walk test with a different effort is performed 1 hour after the baseline test. The second baseline test and the missing test with a different effort takes place within three months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-069 ex 10/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Inhibikase TherapeuticsNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States